Lucent Diagnostics has partnered with Tempus AI to enhance Alzheimer’s disease detection through blood-based biomarker testing.
The collaboration aims to integrate LucentAD® Complete, a multi-biomarker blood test, into Tempus' clinical ordering platform. This initiative seeks to streamline the identification of patients eligible for Alzheimer’s biomarker testing, addressing a significant gap in current clinical practices. With over 7 million Americans affected by Alzheimer’s, many remain undiagnosed or untreated, making this integration crucial for improving patient outcomes.
Tempus Next, an AI-driven platform, will facilitate the identification of care gaps and provide neurologists with actionable insights aligned with clinical guidelines. This approach is designed to make the testing process more efficient and less burdensome for healthcare providers, promoting earlier and more accurate diagnoses.
As the demand for precision medicine grows, collaborations like this one are vital. By making advanced testing more accessible, the partnership between Lucent Diagnostics and Tempus could significantly enhance the standard of care for Alzheimer’s patients, ultimately leading to better treatment options and improved quality of life.